An open-label, multi-center study to evaluate the efficacy and safety of nilotinib in adult patients with gastrointestinal stromal tumors resistant or intolerant to imatinib and or to 2nd line tyrosine kinas (TK) inhibitor.

Trial Profile

An open-label, multi-center study to evaluate the efficacy and safety of nilotinib in adult patients with gastrointestinal stromal tumors resistant or intolerant to imatinib and or to 2nd line tyrosine kinas (TK) inhibitor.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Jan 2011 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Actual patient number is 9 according to ClinicalTrials.gov record.
    • 18 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top